A novel antiplatelet antibody therapy that induces cAMP-dependent endocytosis of the GPVI/Fc receptor γ-chain complex
J. Clin. Invest. Hiroshi Takayama, et al. 118:1785 doi:10.1172/JCI32513 [Go to this article.]

Figure 1
Characterization of YA-Abs over 15 years. (A) YA’s serially diluted plasma stored over 15 years or control solutions containing known amounts of a human/mouse chimera anti-GPVI mAb were incubated with biotin-labeled hGPVI-Fc on streptavidin-coated plates. After washing, the bound Abs were detected using peroxidase-labeled anti-kappa and -lambda chain Abs and subsequent colorimetric reaction. The content of anti-GPVI auto-Abs in the plasma was expressed as an equivalent content of a human/mouse chimera anti-GPVI mAb bound to hGPVI-Fc. Each bar represents the mean of duplicate determinations. (B) Both YA-Abs-88 and -03 were purified from the patient’s plasma stored in 1988 and 2003, respectively, and quantified as described in Methods. Serially diluted YA-Abs-88 (triangles), YA-Abs-03 (circles), mF1201 (diamonds), mF1232 (squares), or mouse IgG (asterisks) as the competing Ab was applied to hGPVI-Fc–immobilized plates followed by the incubation with the peroxidase-labeled mF1201 (left panel) or mF1232 (right panel). After washing, the bound labeled Abs were detected by colorimetric reaction. Data are expressed as the percent of total binding of each peroxidase-labeled mAb without the competitor and are the mean of triplicate determinations.